Abstract:Background A goal of cancer vaccines is to induce strong T cell responses to tumor antigens, but the delivery method, schedule, and formulation of cancer vaccines have not yet been optimized. Adjuvants serve to increase the immune response against vaccine antigens. However, little is known about the impact of adjuvants plus antigen and their delivery schedule on the immunologic milieu in the vaccine-site microenvironment (VSME). We hypothesized that antigen processing and presentation may occur directly in the VSME, that adding the toll-like receptor 3 (TLR3) agonist polyICLC (pICLC) would enhance markers of immune activation, and that the immune signatures would be enhanced further by repeated vaccination in the same skin site rather than after multiple vaccines in different skin locations. Methods Using RNA sequencing, we evaluated VSME biopsies from patients undergoing subcutaneous/intradermal peptide vaccination against melanoma, with incomplete Freund’s adjuvant (IFA) with or without pICLC. Differential gene expression analyses and gene set enrichment analyses were performed using R. False discovery rate corrected p values <0.05 were considered significant. Results We found that addition of peptide antigens to IFA enhanced antigen presentation pathways and a tertiary lymphoid structure gene-signature locally at the VSME. Addition of pICLC to IFA + peptide induced an immunologically favorable VSME 1 week after injection but had little impact on the VSME after three injections, compared with IFA + peptide alone. Repeated same-site injection of IFA + peptide antigens induced a VSME with more dendritic cell activation, Th1 dominance, and TLR adaptor protein gene expression than that induced by injections at different, rotating skin locations. Conclusions These data suggest that the vaccine-site itself may be a critically important location contributing to vaccine immunity rather than just the draining lymph node, that IFA induces a favorable VSME with TLR agonist being most beneficial early in the vaccine course, and that same-site injections lead to persistent stimulation of immune pathways that may be beneficial in eliciting antigen specific T cell expansion.

Poly I:C vaccination drives transient CXCL9 expression near B cell follicles in the lymph node through type-I and type-II interferon signaling

Stimulation of Toll-Like Receptors profoundly influences the titer of polyreactive antibodies in the circulation

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Pathological Role of Interleukin-17 in Poly I:C-Induced Hepatitis

Differential recruitment and activation of mucosal and systemic ILC for improved vaccine design

Mouse CD8α+ DCs and Human BDCA3+ DCs Are Major Producers of IFN-λ in Response to Poly IC

Targeting Lymph Node Niches Enhances Type 1 Immune Responses to Immunization

Lipid Nanoparticle Delivery Alters The Adjuvanticity of The TLR9 Agonist Cpg by Innate Immune Activation in Lymphoid Tissue

Cutaneous vaccination with TLR2 agonists results in the suppression of Th1 responses

Ex vivo Model of Functioning Human Lymph Node Reveals Pivotal Role for Innate Lymphoid Cells and Stromal Populations in Response to Vaccine Adjuvant

Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responses

Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes

IL‐6 expression promoted by Poly(I:C) in cervical cancer cells regulates cytokine expression and recruitment of macrophages

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling

Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity

Intra-Lymph Node Crosslinking of Antigen-Bearing Polymers Enhances Humoral Immunity and Dendritic Cell Activation

Ifn-Producing Killer Dendritic Cells Contribute to the Inhibitory Effect of Poly I : C on the Progression of Murine Melanoma

Intra‐lymph node crosslinking of antigen‐bearing polymers enhances humoral immunity and dendritic cell activation

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo

Cellular basis of differential responsiveness of lymph nodes and spleen to 23-valent Pnu-Imune vaccine

IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients